Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand and sign a consent form, and who are willing and able to follow the study schedule and requirements
• People aged 18 to 70 years old, of any gender, at the time of signing the consent form
• People who can provide a stored or freshly collected tumour tissue sample for testing
• People who have at least one tumour that can be measured using standard imaging criteria (called RECIST v1.1)
• People who have been confirmed by tissue or cell testing to have locally advanced or spread (metastatic) non-small cell lung cancer that cannot be treated with surgery, high-dose radiation therapy, or chemotherapy aimed at cure
• People whose physical functioning is rated as 0 or 1 on a standard activity scale used by doctors (meaning fully active or able to carry out light activity)
• People whose life expectancy is estimated to be at least 12 weeks
• People whose liver, kidneys, and other organs are working at a good enough level (as assessed by the trial site)
• People who agree to use a highly effective method of contraception during the study — this applies to men whose partners could become pregnant, and to women who are able to have children

Who may not be able to join:

• People who have brain metastases (cancer that has spread to the brain) that are active or causing symptoms
• People who have been diagnosed with another type of cancer, unless it was fully cleared at least 5 years ago and treatment has ended — certain skin cancers, early-stage bladder cancer, cervical cancer in situ, breast ductal cancer in situ, or papillary thyroid cancer with a clear record of cure may be exceptions (confirm with trial site)
• People who have uncontrolled build-up of fluid around the lungs, abdomen, or heart
• People whose cancer-related pain is not well controlled
• People who received any cancer treatment within 4 weeks before starting the study
• People who received higher-dose radiation therapy outside the chest within 28 days before starting, higher-dose radiation to the chest within 24 weeks before starting, or lower-dose radiation therapy within 14 days before starting (confirm with trial site)
• People who are currently in another clinical trial, or whose last dose in a previous clinical trial was less than 4 weeks ago (or less than 5 half-lives of the study drug, whichever is longer)
• People who had major surgery requiring general anaesthesia within 28 days before the study, minor or diagnostic surgery within 7 days before the study, or who are expected to need planned surgery during the trial
• People whose side effects from previous cancer treatment have not sufficiently recovered (confirm with trial site)
• People who received medicines to suppress the immune system within 14 days before starting the study
• People who have a history of lung inflammation (interstitial or non-infectious pneumonia) that required steroid treatment, or who currently have or are suspected to have this condition
• People who have any active, known, or suspected autoimmune disease (a condition where the immune system attacks the body)
• People with serious heart or blood vessel (cardiovascular or cerebrovascular) conditions
• People who had a severe infection within 28 days before starting the study
• People with active hepatitis B or active hepatitis C
• People who had active tuberculosis within 1 year before enrolling in the study
• People who had significant bleeding or a high tendency to bleed within 1 month before starting the study
• People with a history of immune deficiency
• People who received a live vaccine within 28 days before starting the study, or who would need one during the study
• Women who are pregnant or planning to become pregnant during the study
• People with uncontrolled mental health conditions, or issues such as alcohol, drug, or substance misuse, or who are subject to criminal detention
• People who the trial doctor determines have any other circumstances that could increase risk or interfere with the study
• People with a bleeding tendency, high bleeding risk, blood clotting problems, or a tendency to form clots — this applies specifically to those receiving bevacizumab as part of the study
• People with poorly controlled high blood pressure (systolic at or above 150 mmHg and/or diastolic at or above 100 mmHg despite treatment), or a history of hypertensive crisis or severe blood-pressure-related brain conditions — for those receiving bevacizumab
• People who had a major blood vessel disease in the 6 months before starting — for those receiving bevacizumab
• People who used full-dose blood-thinning or clot-dissolving medicines in the 7 days before starting (certain low-dose preventive uses may be allowed — confirm with trial site) — for those receiving bevacizumab
• People who used or need to use certain blood-thinning medicines such as aspirin, clopidogrel, or similar platelet-inhibiting drugs within 7 days before starting — for those receiving bevacizumab
• People with severe wounds that have not healed, active ulcers, or untreated broken bones — for those receiving bevacizumab
• People who had a gastrointestinal perforation (a hole in the gut) in the 6 months before starting, or who show signs of bowel obstruction during screening — for those receiving bevacizumab
• People whose scans show that the tumour is surrounding or growing into major blood vessels — for those receiving bevacizumab
• People who have previously received systemic treatment with drugs that target blood vessel growth (such as bevacizumab, anlotinib, or similar medicines) — for those in the bevacizumab group

Important: Always verify eligibility with the trial site directly before applying.